The COVID-19 pandemic significantly impacted the circulation, seasonality, and disease burden of viral respiratory infections. This study aimed to evaluate the impact of SARS-CoV-2 on the frequency of viral respiratory infections at a teaching hospital in Southern Italy by comparing data from before, during, and after the COVID-19 pandemic and by investigating how the emergence of SARS-CoV-2 affected the circulation and seasonality of other respiratory viruses. This retrospective and prospective study was performed on de-identified nasopharyngeal specimens classified as pre-COVID-19 (before 15 March 2020), during-COVID-19 (from 16 March 2020 to 5 May 2023), and post-COVID-19 (from 6 May 2023 to 31 December 2024). Overall, 790 out of 3930 (20%) patient samples tested positive for at least one respiratory virus. The mean age of patients was 60 ± 19 years, with significant positivity rates observed in the 65–98 age group (p ≤ 0.05) across all periods. In the pre-COVID-19 period, the most prevalent virus was influenza A (47.5%, 47/99), followed by the human rhinovirus (19.2%, 19/99). During the COVID-19 pandemic, SARS-CoV-2 was the most prevalent (64.9%, 290/447), before decreasing to 38% (92/244) after the pandemic, while influenza A’s positivity prevalence increased to 14.3% (35/244). Rhinovirus/enterovirus remained relatively stable throughout all periods. The pandemic notably altered viral co-infection dynamics, with its effects lasting into the post-COVID-19 period. Specifically, a marked decrease in influenza A circulation was observed, while respiratory syncytial virus (RSV) epidemiology remained stable and significant co-circulation of rhinovirus/enterovirus with SARS-CoV-2 persisted. Therefore, since COVID-19 and influenza affect the same high-risk groups, those individuals must be vaccinated against both viruses.

Background: Sepsis remains a major cause of morbidity and mortality in both developed and limited-resource countries. Despite over a century of research, accurate biomarkers for reliable diagnosis and prognosis in critically ill patients have yet to be established. Methods: This multicenter retrospective observational study aims to evaluate serum levels of Calprotectin, Azurocidin, cytokines, chemokines, procalcitonin (PCT) and C-Reactive Protein (CRP) in 15 healthy volunteers (controls), 15 non-infectious SIRS patients, 92 alive septic patients (Sepsis_A) and 29 dead septic patients (Sepsis_D). Results: Most biomarkers showed significantly higher serum concentrations in septic patients compared with controls, with IL-4 being increased only in the Sepsis_D group. In addition, several markers, including Calprotectin, Azurocidin, IL-6, IL-8, IL-10, TNF-α, and IL-35, were progressively elevated from SIRS to Sepsis_A and Sepsis_D cohorts, reflecting disease severity. All biomarkers showed good diagnostic performance for predicting Gram-negative bacteremia, although their accuracy in discriminating survivors from non-survivors was relatively low. Conclusions: In conclusion, calprotectin, azurocidin, IL-8, TNF-α, and IL-35 may assist clinicians in identifying Gram-negative bacteremia in septic patients; however, their prognostic value appears to be limited.

If the number of viral hepatitis infections is to be decreased worldwide, and the World Health Organization (WHO) elimination targets are to be achieved by 2030, this requires determining the burden of infection according to the WHO’s test-and-treat approach. In 2014, the introduction of Direct-Acting Antivirals (DAAs) revolutionized the management of Hepatitis C Virus (HCV); another improvement came in 2020, when the use of bulevirtide (BLV) was authorized as a treatment for chronic Hepatitis D Virus (HDV) infection, showing good efficacy. The present observational study was carried out between 2019 and 2024. The diagnosis of viral hepatitis was carried out by routine assays. HDV typing was performed by Sanger sequencing and phylogenetic analysis. Overall, the HCV antibody prevalence was 3.4% in the studied time span, and it was higher in males than in females (59% vs. 41%). In viremic patients, HCV1b (33%) and HCV2a/2c (25%) were the most common subtypes. The overall HCV viremic rate declined in 2022 (2.8%). Unlike HCV, 71.4% of HDV viremic patients were females, and they had a median age of 58 years. The viral load of HDV RNA ranged from 20 IU/mL to 8 million IU/mL. Viral genotypes were classified as HDV1c and HDV1e. In this study, we highlight the prevalence of HCV/HDV infections and their genotype evolution in Southern Italy, underscoring the urgent need to enhance screening and linkage to care. Finally, we quantify the burden of active infections in order to provide data from real-life settings, and we describe the virological status of people living with HCV or HBV/HDV, who may experience significant benefits in terms of liver-related mortality after DAA or BLV treatment.

Emerging viral infections pose significant challenges for clinical management and public health, particularly in non-endemic settings. Rapid and accurate diagnostics are essential to guide therapy, implement infection control measures, and support epidemiological surveillance. Traditional methods, including viral culture and early serology, are often limited by long turnaround times or low sensitivity in the acute phase of infection. In this study, we discuss two cases reported for the first time of emerging viral infections in Calabria, Southern Italy, diagnosed using rapid molecular diagnostics. Clinical samples from patients with suspected emerging viral infections in a non-endemic setting were analyzed using rapid cartridge-based molecular assays and serological testing. The first case describes a 54-year-old man with confirmed Monkeypox virus (MPXV) infection, identified through a targeted cross-priming amplification assay (CPA), yielding results within ∼55 minutes and enabling immediate clinical management and isolation. The second case involves a 58-year-old woman with dengue virus serotype 2 (DENV-2) infection detected via a multiplex syndromic molecular panel within 60 minutes. Notably, serological testing was initially negative for both IgM and IgG, with seroconversion occurring one week later, consistent with the high sensitivity of molecular assays for detecting viral RNA during the acute phase. These cases highlight the critical role of rapid molecular diagnostics in timely pathogen identification, early clinical intervention, and support for public health measures. Our findings underscore the importance of integrating fast molecular assays into diagnostic pathways, promoting clinician awareness, and combining surveillance with preventive strategies, such as vaccination for travelers.